GSK lures another Genentech executive to its team
GlaxoSmithKline (LSE: GSK) today revealed is has appointed Kevin Sin as senior vice president and head of worldwide business development for pharmaceuticals research and development.
In this position, Mr Sin will play a critical role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients, reporting to Dr Hal Barron, chief scientific officer and president of R&D at GSK,and be based in San Francisco.
Mr Sin will join the UK pharma major in July from Roche (ROG: SIX) subsidiary Genentech, where he is currently VP and global head of oncology business development, responsible for partnering, acquisition and licensing activities for novel oncology therapeutics. He has worked within the pharmaceutical and life sciences industry for over 20 years in roles spanning business development, legal and research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze